459856-12-3

Usage

Uses

Used in Organic Synthesis:
2-METHYL-6-METHOXYPYRIDINE-3-BORONIC ACID is used as a building block in organic synthesis for the construction of various biologically active molecules. Its unique structure allows for the formation of carbon-carbon bonds, making it a valuable intermediate in the synthesis of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-METHYL-6-METHOXYPYRIDINE-3-BORONIC ACID is used as a key intermediate in the preparation of pharmaceuticals. Its reactivity and structural features enable the development of new drugs with potential therapeutic applications.
Used in Agrochemicals:
2-METHYL-6-METHOXYPYRIDINE-3-BORONIC ACID is also utilized in the agrochemical industry for the synthesis of various agrochemicals. Its ability to form carbon-carbon bonds makes it a valuable component in the development of new pesticides and other agricultural chemicals.
Used as a Reagent in the Suzuki-Miyaura Coupling Reaction:
2-METHYL-6-METHOXYPYRIDINE-3-BORONIC ACID is used as a reagent in the Suzuki-Miyaura coupling reaction, a widely used chemical reaction for the formation of carbon-carbon bonds. This reaction is essential in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other fine chemicals.

InChI:InChI=1/C7H10BNO3/c1-5-6(8(10)11)3-4-7(9-5)12-2/h3-4,10-11H,1-2H3

Upstream product

• 5419-55-6 Triisopropyl borate 
• 126717-59-7 3-bromo-6-methoxy-2-methylpyridine 

Downstream Products

• 1279107-04-8 4-(2-(6-methoxy-2-methylpyridin-3-yl)-1-(trifluoromethylsulfonyl)-1-1H-indol-5-yl)-3-methylbenzonitrile 
• 503184-36-9 2'-benzyloxy-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl 
• 1020334-61-5 C₂₄H₃₀N₂O₄ 

Relevant academic research and scientific papers

Fluorine-free blue-green emitters for light-emitting electrochemical cells

There is presently a lack of efficient and stable blue emitters for light-emitting electrochemical cells (LEECs), which limits the development of white light emitting systems for lighting. Cyclometalated iridium complexes as blue emitters tend to show low photoluminescence efficiency due to significant ligand-centred character of the radiative transition. The most common strategy to blue-shift the emission is to use fluorine substituents on the cyclometalating ligand, such as 2,4-difluorophenylpyridine, dFppy, which has been shown to decrease the stability of the emitter in operating devices. Herein we report a series of four new charged cyclometalated iridium complexes using methoxy- and methyl-substituted 2,3′-bipyridine as the main ligands. The combination of donor groups and the use of a cyclometalated pyridine has been recently reported for neutral complexes and found electronically equivalent to dFppy. We describe the photophysical and electrochemical properties of the complexes in solution and use DFT and TDDFT calculations to gain insights into their properties. The complexes exhibit bluish-green emission with onsets around 450 nm, which correspond to the maximum emission at 77 K. Furthermore, photoluminescence quantum yields in solution are all above 40%, with the brightest in the series at 66%. Finally, LEECs were prepared using these complexes as the emissive material to evaluate the performance of this particular design. Compared to previously reported devices with fluorine-containing emitters, the emitted colours are slightly red-shifted due to methyl substituents on the coordinating pyridine of the main ligand and overall device performances, unfortunately including the stability of devices, are similar to those previously reported. Interestingly within the series of complexes there appears to be a positive effect of the methoxy-substituents on the stability of the devices. The poor stability is therefore attributed to the combination of cyclometalated pyridine and methoxy groups. the Partner Organisations 2014.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1, 5-a]-1,3,5-triazines: Potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists

This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF1 IC50 = 6.1 ± 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.

1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE

The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]

4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.